Exaggerations and Misrepresentations Have No Place in Science Policy Debates
By Jeremy Gruber,
Council for Responsible Genetics
| 02. 15. 2013
Yesterday
Intelligence Squared held a debate (
watch it in its entirety here) on whether we should prohibit genetically engineered babies. Arguing for the motion were CRG Board Chair Professor Sheldon Krimsky and Robert Winston, professor at Imperial College London. Arguing against the motion was Nita Farahany, professor at Duke University and a member of the Presidential Commission for the Study of Bioethical Issues and Lee Silver, professor at Princeton University.
The debate quickly turned to focus on mitochondrial disease, a group of disorders caused by dysfunctional mitochondria, the organelles that generate energy for the cell and a new technique for treating such diseases that would, for the first time, allow the creation of babies whose genes have been intentionally altered by replacing the mitochondrial DNA. In focusing on this, and exclusively this element of genetic engineering, opponents of a ban managed to avoid any debate over genetic engineering purely for enhancement purposes. Indeed, Professor Silver seemed to distance himself from the more controversial opinions he espoused in his book,
Remaking Eden: How Genetic Engineering and Cloning Will Transform...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...